- Home
- PSO vs PCVX Comparison
PSO vs PCVX Comparison
Compare PSO & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSO
- PCVX
- Stock Information
- Founded
- PSO 1844
- PCVX 2013
- Country
- PSO United Kingdom
- PCVX United States
- Employees
- PSO N/A
- PCVX N/A
- Industry
- PSO Books
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- PSO Consumer Discretionary
- PCVX Health Care
- Exchange
- PSO Nasdaq
- PCVX Nasdaq
- Market Cap
- PSO 9.5B
- PCVX 4.4B
- IPO Year
- PSO 2000
- PCVX 2020
- Fundamental
- Price
- PSO $14.17
- PCVX $35.28
- Analyst Decision
- PSO
- PCVX Strong Buy
- Analyst Count
- PSO 0
- PCVX 10
- Target Price
- PSO N/A
- PCVX $136.50
- AVG Volume (30 Days)
- PSO 720.0K
- PCVX 1.5M
- Earning Date
- PSO 01-01-0001
- PCVX 08-05-2025
- Dividend Yield
- PSO 2.24%
- PCVX N/A
- EPS Growth
- PSO 20.49
- PCVX N/A
- EPS
- PSO 0.79
- PCVX N/A
- Revenue
- PSO $4,446,837,010.00
- PCVX N/A
- Revenue This Year
- PSO $3.66
- PCVX N/A
- Revenue Next Year
- PSO $3.94
- PCVX N/A
- P/E Ratio
- PSO $16.94
- PCVX N/A
- Revenue Growth
- PSO N/A
- PCVX N/A
- 52 Week Low
- PSO $12.99
- PCVX $27.66
- 52 Week High
- PSO $17.90
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- PSO 33.09
- PCVX 54.47
- Support Level
- PSO $14.36
- PCVX $31.79
- Resistance Level
- PSO $14.91
- PCVX $36.89
- Average True Range (ATR)
- PSO 0.15
- PCVX 1.55
- MACD
- PSO -0.01
- PCVX 0.37
- Stochastic Oscillator
- PSO 1.53
- PCVX 68.43
About PSO Pearson Plc
Pearson PLC listed in the U.K., is an educational provider. The company has been divesting non-core businesses such as the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider. While Pearson's primary activity centers on higher education, the firm also operates in providing clinical assessments, professional certification, and testing.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.